LLY Stock Recent News
LLY LATEST HEADLINES
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.
Examine Lilly's (LLY) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.
The executive order that Donald Trump has signed over the last 24 hours could have a significant effect on pharmaceutical companies, and as a result, we should be paying attention to this sector.
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies, including Pfizer and Nordstrom, met the "safer" qualification with free cash flow yields exceeding dividend yields. Analysts estimate net gains of 19.58% to 41.46% for top Fortune 50 WMA companies by May 2026, with Novo Nordisk leading.
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Eli Lilly and Co (NYSE:LLY)'s weight loss drug Zepbound (tirzepatide) has shown superior results compared to Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in a direct clinical trial, marking the first head-to-head comparison between the two leading obesity treatments. In the 72-week SURMOUNT-5 trial, participants on Zepbound lost an average of about 50 pounds (22.8 kg), equating to approximately 20.2% of their body weight.